Galderma Group AG Stock Price

SWX:GALD Community·CHF 36.1b Market Cap

3 Narratives written by author
0 Comments on narratives written by author
28 Fair Values set on narratives written by author

Author Program NEW Create Narrative

GALD Share Price Performance

CHF 154.95

9.55 (6.57%)

CHF 137.52

Fair Value

CHF 154.95

9.55 (6.57%)

12.7% overvalued

CHF 137.52

Fair Value

CHF 154.95

CHF 137.52

CHF 188.31

CHF 246.01

Thu, 3 Sep 26

Fair ValueCHF 137.52

Share Pricen/a

GALD Community Narratives

AnalystLowTarget's

Fair Value

Fair Value CHF 137.52 12.7% overvalued

Rising Global Controls And Biosimilar Risks Will Squeeze Margins

AnalystConsensusTarget's

Fair Value

Fair Value CHF 188.31 17.7% undervalued

GALD: Execution On New Aesthetic Launches And Margin Gains Will Sustain Upside

AnalystHighTarget's

Fair Value

Fair Value CHF 246.01 37.0% undervalued

Aging Global Demand And Minimally Invasive Procedures Will Reinvent Aesthetics

Galderma Group

12.7% overvalued

Rising Global Controls And Biosimilar Risks Will Squeeze Margins

AnalystLowTarget

Updated 3 Sep

Read Narrative

Galderma Group

37.0% undervalued

Aging Global Demand And Minimally Invasive Procedures Will Reinvent Aesthetics

AnalystHighTarget

Updated 30 Jul

Read Narrative

Galderma Group

17.7% undervalued

GALD: Execution On New Aesthetic Launches And Margin Gains Will Sustain Upside

AnalystConsensusTarget

Updated 1 Jul

Read Narrative

Trending Discussion

No trending discussion available.

Snowflake Analysis

Solid track record with reasonable growth potential.

0 Risks

4 Rewards

View Full Analysis

Galderma Group AG Key Details

Last Reported Earnings

Jun 30, 2026

Next Reporting Earnings

n/a

: 3.70
: 69.37%
: 14.57%
: 30.8%

View Full Analysis

About GALD

Founded: 1981
Employees: 7676
CEO: Flemming Ornskov
WebsiteView website: www.galderma.com

Galderma Group AG operates as a dermatology company worldwide. The company delivers a science-based portfolio of brands and services for the dermatology market, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. Its portfolio of flagship brands includes Azzalure, ALLUZIENCE, Dysport, Restylane, Restylane Skinboosters, Sculptra, Cetaphil, ALASTIN, Soolantra, Epiduo, Epiduo Forte, Differin, AKLIEF, Oracea, Metvix, NEMLUVIO, Relfydess, Benzac, and Loceryl in therapeutic dermatology. The company was founded in 1981 and is headquartered in Zug, Switzerland.